

IDEAL4RWE

Introductory Seminar

April 19, 2022



Objectives for today

Digital Institute for Cancer Outcomes Research	5 mins	
dership programme itment expected	10 mins	
outcome study in ovarian cancer: nieved	30 mins	

	Introduce DIGICORE – The Digital Institute for Cancer Outcomes Research	5 mins
× × × ×	Outline the IDEAL4RWE leadership programme • Rationale • Benefits to you, and commitment expected	10 mins
$\frac{2}{2}$	Share a case example of an outcome study in ovarian cancer:Outcomes and insights achievedLessons learned	30 mins
$\overset{\bigcirc}{\rightarrowtail}$	Next steps & Q+A How to sign up for the full programme What you need to do before the summer 	15 mins

DigiCore

Introducing speakers



James Anderson

Leadership Development Advisor, DIGICORE



Professor Geoff Hall

Chief Clinical Informatics Officer, Leeds, and ORWIC study lead



Mariana Guergova-Kuras

IQVIA Country Lead, France, for Oncology Evidence Network



Will Sopwith RWE Advisor, DIGICORE




Piers Mahon

Commercial Research Manager, DIGICORE



DIGICORE is a new collaboration that aims to transform and digitise cancer outcome research in Europe




Benefits and rationale

- For Cancer Centres, pool cancer data across sites for improved translational research
- For **Patients**, broader trial access and in future better outcomes
- For IQVIA, drive commercial multi centre, international real world evidence projects in precision oncology and drive precision trial recruitment
- For All Grow clinical evidence base for molecular diagnostic tests in improving outcomes and accelerate reimbursement for all vendors



Individual centre members of DIGICORE network in 16 countries



Real World Evidence (RWE) presents a huge opportunity for DIGICORE to transform outcomes research and improve patient care

RWE can improve patient care			Significant funds are coming available for digital infrastructure/RWE		
(AAA)	Benchmarking outcomes and standard of care across countries to identify potential care improvements		Potential source of funding next 5 years	Total funding (estimate)	Of which digital infrastructure (estimate)
	Developing patient cohorts in rare cancers		Recovery and resilience facility Cancer mission	€100bn	€12bn*
¥)	Linking clinical information to biomarkers to better understand precision medicine			€2.6bn	€0.1 to 0.2bn**
	Using external comparators to complement single arm clinical trials			C2.0011	
	Assessing use and value of diagnostics		IHI + life sciences industry	€500bn	€1.5 to 2bn***

*Digital transition in healthcare funding estimates; **5 to 10% total; ***IHI and in-house research programme funding vs. global R&D spend in Cancer Source: European Commission Recovery and Resilience Scoreboard, Dec 2021

To realise DIGICORE's vision we will need a new generation of outcome researchers to digitise cancer control

DIGICORE is investing in infrastructure: "A better digital microscope" for cancer outcomes research...



... but to use it well will need new research skills and leadership inside cancer centres

Solution

IQVIA – DIGICORE Early Career Leadership Programme for Real World Evidence (IDEAL4RWE)

DigiCore

IDEAL4RWE will build these skills among emerging research leaders


္က ^{င္တာ} Who?	 Under 45, clinicians, data scientists etc. Interested in outcome research and ambitious to lead digital revolution in RWE. Employed in healthcare/not-for-profit in Europe 	WI By April 2
? What?	 Training on both technical and leadership skills for RWE Based around delivery of an international proof-of-concept study 	 A cohe (focus involv progration
How?	 Mix of training styles: Face-to-face and virtual Full programme involves "test" application – funding available 	€150K
When?	 Starts in Q2 2022 – free "taster" programme RWE studies start in Q4 2022/Q1 2023 Concludes H1 2023 	develo outpu • A plan
E T&Cs?	 Open to multi-centre teams of early career researchers Must have support of their centre for some research time Their centre must join DIGICORE 80% study funds spent in centres contracted with IQVIA 	2023 c

here we want to get to

2023

- ort of 20-25 future leaders on clinicians but others red) trained through the whole mme – Training budgets of + staff time
- oof of concept studies pped, with **3 delivering analytic** ts (study fund of €210k)
- for **future cohorts** from on





Training

Team activity

Part 2: Learning by doing (July 2022 to April 2023)

Advanced team-based training & protocol – Intensive

Jul 2022-Apr 2023

103 Leadership training/201 Advanced RWE technical training

Teams refine and drive pilot RWE programmes. Selected teams (3-5) receive PoC study funding from IQVIA

Teams apply for funding



Outcome study funding applicationProtocol

- Common data model
- Evidence of progress to date
- Up to €210k total for 3-4 studies
- Awarded by independent advisory board

	s get to output
Key outputs • On-smal cel lung cancer • Patient characteristics (e.g. histology, biomarker • Treatment patients (ines of chemotherapy, and) • Outcomes from diagnosis, recurrence(s) to deal	surgery)



An expert panel of internationally renowned researchers will provide advice and allocate funding throughout the programme

Members of IDEAL4RWE Leadership Advisory Board (LAB)



Prof David Cameron (Edinburgh University) – Co-chair

Prof Iwona Lugowska (Oncology Institute,

Poland) – Co-chair



Prof Massimo di Maio (Oncology Department, Turin)



Prof Janne Vehreschild (German Centre for Infection Research)



Dr Sue Cheeseman (Leeds Teaching Hospital)



Dr Anne-Sophie Hamy-Petit (University of Paris)



Prof Andre Dekker (Maastricht Comprehensive Cancer Centre)



Gilliosa Spurrier Bernard (Co-chair WECAN)



Dr Mariana Guergova-Kuras (IQVIA)



James Anderson (DIGICORE)




Setting you up for future success in real world research

The first cohort at the cutting edge of the digital revolution

What you get

New skills **Face-to-face** leadership development training (places limited) 6-8 virtual seminars from leading **Network** of Potential **funding** A proof-of-concept study researchers for an outcome study like-minded collaborators and to support future funding (up to €210k for 3+ studies) applications mentorship from **leading Peer learning** international researchers Coaching

What you need to commit





Case study: ORWIC

≣IQVIA

The Leeds Teaching Hospital



- Leeds General Infirmary
- Chapel Allerton Hospital
- · Seacroft Hospital
- Wharfedale Hospital

NHS

The Leeds **Teaching Hospitals** NHS Trust


http://www.leedsth.nhs.uk/

- · The Leeds Teaching Hospitals NHS Trust (LTHT) is one of the largest trusts in the UK
- · The trust has 6 sites, including paediatric centre
- One of the largest teaching hospitals in Europe
- Treats ~5% of UK population with 1,200 inpatient beds together with critical care and day case beds
- · Local district hospital for population of Leeds (~1M)
- Specialist cancer services to Yorkshire (~2.7M)
- · Regional centre for a number of specialist cancer (~5.7M)
- Largest provider of specialist services in UK
- Largest integrated Cancer Centre in UK


.01



ORWIC Q&A



I'm interested! What do I need to do?



Registrants will also get access to three further training seminars, and FAQs on a SharePoint platform



Study team – leadership team (July) and implementation team (Protocol submission)

You will need to start by identifying your leadership team

By July – leadership team

Role

- The "organising minds" for the international outcomes study
- Responsible for protocol, planning, resourcing, overall delivery, dissemination
- The future lead authors for the work
- Generally but not exclusively clinician researchers

Composition

- At least 3 sites/institutions from at least 3 countries all in Europe
- Max 1 person per site/institution
- 1 patient representative
- Up to 1 additional team member (e.g., other science discipline)
- <45 will be given priority
- Commitment to 1 day/week/team member*

By October – delivery team

Role

- The delivery team for the study all activities required for study delivery
- A range of different functions

Composition

- As for leadership team and also...
- At least two additional sites (may be outside Europe)
- Additional functional expertise as required (e.g., epi, data science, stats, clinical coders, additional clinicians) no age restriction

*Preferably each team member can commit 1 day a week – where not possible, ½ day week with additional ½ day support (e.g., from research scientist) will be considered



The Digital Institute for Cancer Outcomes Research

15

We will be looking for individuals and teams who demonstrate enthusiasm, commitment and a vision for outcomes research

July submission and application assessment criteria

Content of submission

- Short bios of all team members and relevant and complementary experience (2-3 pages)
- TA and study objectives (1-2 pages)
- Cohort size by institution (1/2 page)
- Identified target data items and local formats (1 page table)
- Site-level legal basis for and approach to processing (1/2 – 1 page)
- Short term project plan (1 page)
- Evidence of institutional support (Letter of support)

Criteria for assessment

Assessment of initial study proposals will include evaluation of:

- Host centres of team members the suitability of the centres represented as collaborator in a proof of concept network
- 2. Team skill mix the ability for the named collaborators to deliver the study
- 3. Project proposal quality of the initial proposal outline
- 4. **Project delivery –** feasibility of the initial proposal within timescale




Questions?





What happens next?





Thank you

